Virtual Library

Start Your Search

Jianfa Shen

Author of

  • +

    P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.01-113 - Analysis of Clinicopathological Features and Clinical Efficacy of Crizotinib in ROS1 Positive Non-Small Cell Lung Cancer (ID 11100)

      16:45 - 18:00  |  Author(s): Jianfa Shen

      • Abstract
      • Slides


      ROS1 gene-rearrangement in non-small-cell lung cancer (NSCLC) patients has recently been identified as a driver gene and benefited from crizotinib treatment. The aim of this study is to explore clinicopathological features and clinical efficacy of crizotinib in c-ros oncogene 1 receptor tyrosine kinase (ROS1) positive non-small cell lung cancer (NSCLC).

      a9ded1e5ce5d75814730bb4caaf49419 Method

      A retrospective analysis of 2617 cases of NSCLC from January 2013 to December 2016, ROS1 fusion gene were detected by real-time reverse transcriptase-polymerase chain reaction (RT-PCR), fluorescent in situ hybridization (FISH) or next-generation sequencing (NGS) technique and part ROS1 fusion gene positive patients were received oral treatment with crizotinib.

      4c3880bb027f159e801041b1021e88e8 Result

      ROS1 fusion was found in 67 of 2167 cases (2.56%). 21 cases were male and 46 cases were female. The median age was 68 years old. Among these cases, 59 (88.05%) were adenocarcinoma and 8 were non-adenocarcinoma. According the TNM staging,4 cases were Ⅰ-Ⅲa and 63(94.02%) cases were Ⅲb-Ⅳ. EGFR gene status included 60 cases wild type, 1 case co-mutation and 6 cases unknown. There were statistical difference in sex, TNM staging and EGFR gene status between ROS1 fusion gene positive and negetive patients (P<0.001). 23 patients were received oral treatment with crizotinib and PR, SD, PD patients were 13 (56.52%), 5 (21.74%) and 5 (21.74%) respectively. The ORR was 56.52% and DCR was 78.26%. Of all the cases, median PFS was14.5 months and OS was 27.3 months. The one-year PFS was 50.4%.There were no difference of median PFS in age, sex, smoking history, PS score, pathology type, TNM staging ,TP53 gene status, EGFR gene status and the first line crizotinib treatment whether or not by single and multiple factor analysis. The 3/4 grade treatment-related adverse events were gastrointestinal disturbance, followed by increased transaminase.

      8eea62084ca7e541d918e823422bd82e Conclusion

      The rate of ROS1 fusion of NSCLC is lower. Crizotinib is an effective and safe drug for the treatment of ROS1 positive advanced NSCLC.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.